Opus Genetics (IRD) Competitors $0.95 +0.09 (+9.83%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$0.98 +0.03 (+2.63%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock IRD vs. TLSA, NKTX, CHRS, LYEL, SCPH, LRMR, CTNM, KRRO, OGI, and EPRXShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Tiziana Life Sciences (TLSA), Nkarta (NKTX), Coherus BioSciences (CHRS), Lyell Immunopharma (LYEL), scPharmaceuticals (SCPH), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), Korro Bio (KRRO), Organigram (OGI), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Tiziana Life Sciences Nkarta Coherus BioSciences Lyell Immunopharma scPharmaceuticals Larimar Therapeutics Contineum Therapeutics Korro Bio Organigram Eupraxia Pharmaceuticals Tiziana Life Sciences (NASDAQ:TLSA) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings. Do analysts rate TLSA or IRD? Opus Genetics has a consensus price target of $7.33, suggesting a potential upside of 671.93%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Opus Genetics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, TLSA or IRD? Opus Genetics has higher revenue and earnings than Tiziana Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$17.69MN/AN/AOpus Genetics$10.99M3.93-$9.99M-$2.15-0.44 Do insiders & institutionals have more ownership in TLSA or IRD? 15.0% of Opus Genetics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 6.6% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to TLSA or IRD? In the previous week, Tiziana Life Sciences had 1 more articles in the media than Opus Genetics. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 1 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.89 beat Tiziana Life Sciences' score of 0.11 indicating that Opus Genetics is being referred to more favorably in the news media. Company Overall Sentiment Tiziana Life Sciences Neutral Opus Genetics Very Positive Which has more risk and volatility, TLSA or IRD? Tiziana Life Sciences has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Is TLSA or IRD more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Opus Genetics' net margin of -324.45%. Tiziana Life Sciences' return on equity of 0.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Opus Genetics -324.45%-63.65%-56.94% Does the MarketBeat Community believe in TLSA or IRD? Tiziana Life Sciences received 90 more outperform votes than Opus Genetics when rated by MarketBeat users. However, 100.00% of users gave Opus Genetics an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote. CompanyUnderperformOutperformTiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Opus GeneticsOutperform Votes6100.00% Underperform VotesNo Votes SummaryOpus Genetics beats Tiziana Life Sciences on 8 of the 15 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.21M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.877.4422.5718.48Price / Sales3.93242.70395.64103.60Price / CashN/A65.8538.1834.62Price / Book0.436.516.774.25Net Income-$9.99M$143.21M$3.22B$248.23M7 Day Performance18.75%1.97%1.46%0.89%1 Month Performance4.40%6.89%3.98%3.53%1 Year PerformanceN/A-2.52%16.14%5.09% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics2.1417 of 5 stars$0.95+9.8%$7.33+671.9%N/A$43.21M$10.99M-0.8714Positive NewsHigh Trading VolumeTLSATiziana Life Sciences0.4731 of 5 stars$1.13+5.6%N/A+110.0%$132.04MN/A0.008Short Interest ↑News CoverageNKTXNkarta2.832 of 5 stars$1.85+2.2%$14.86+703.1%-68.3%$131.27MN/A-0.98140Upcoming EarningsPositive NewsCHRSCoherus BioSciences3.532 of 5 stars$1.06-5.4%$5.38+407.1%-47.4%$129.81M$266.96M-13.25330Upcoming EarningsAnalyst ForecastNews CoverageGap DownLYELLyell Immunopharma3.4188 of 5 stars$0.44+0.9%$1.00+128.5%-78.1%$129.25M$61,000.00-0.55270Upcoming EarningsNews CoveragePositive NewsSCPHscPharmaceuticals3.7171 of 5 stars$2.56-0.4%$14.00+446.9%-43.0%$128.73M$36.33M-1.3530News CoveragePositive NewsLRMRLarimar Therapeutics2.035 of 5 stars$2.01+5.2%$19.63+876.4%-61.5%$128.70MN/A-1.7530Earnings ReportUpcoming EarningsOptions VolumeNews CoverageCTNMContineum Therapeutics1.9983 of 5 stars$4.95+7.1%$24.80+401.0%-73.7%$128.07M$50M-1.0131News CoverageKRROKorro Bio1.4849 of 5 stars$13.64-1.9%$120.43+782.9%-68.7%$128.07M$2.27M-1.4570Analyst ForecastAnalyst RevisionNews CoveragePositive NewsOGIOrganigram0.8342 of 5 stars$1.00-6.5%N/A-45.3%$126.26M$166.12M-2.63860EPRXEupraxia Pharmaceuticals2.9612 of 5 stars$3.48+5.8%$10.50+201.7%+49.6%$124.76MN/A-4.8329Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Tiziana Life Sciences Alternatives Nkarta Alternatives Coherus BioSciences Alternatives Lyell Immunopharma Alternatives scPharmaceuticals Alternatives Larimar Therapeutics Alternatives Contineum Therapeutics Alternatives Korro Bio Alternatives Organigram Alternatives Eupraxia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IRD Stock Free IRD Stock Alerts